[go: up one dir, main page]

UY27389A1 - Conjugados de complejos metálicos macrocíclicos con biomoléculas y su uso para la preparación de medios de diagnóstico por resonancia magnética nuclear, radiodiagnóstico y radioterapia - Google Patents

Conjugados de complejos metálicos macrocíclicos con biomoléculas y su uso para la preparación de medios de diagnóstico por resonancia magnética nuclear, radiodiagnóstico y radioterapia

Info

Publication number
UY27389A1
UY27389A1 UY27389A UY27389A UY27389A1 UY 27389 A1 UY27389 A1 UY 27389A1 UY 27389 A UY27389 A UY 27389A UY 27389 A UY27389 A UY 27389A UY 27389 A1 UY27389 A1 UY 27389A1
Authority
UY
Uruguay
Prior art keywords
conjugates
radiodiagnosis
biomolecules
preparation
metal complexes
Prior art date
Application number
UY27389A
Other languages
English (en)
Inventor
J Platzek
H S-Willich
G Michl
T Frenzel
D Sulzle
H Bauer
B Raduchel
H Weinmann
Heiko Schirmer
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY27389A1 publication Critical patent/UY27389A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/143—Peptides, e.g. proteins the protein being an albumin, e.g. HSA, BSA, ovalbumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a conjugados de complejos metálicos macrocíclicos con biomoléculas y a su preparación. Los conjugados son aptos como medios de contraste en el diagnóstico por NMR y radiodiagnóstico y como sustancia radioterapéutica. Con ligandos especiales de los macrociclos se logra una elevada relajación y se posibilita un ajuste fino de la relajación.
UY27389A 2001-07-20 2002-07-17 Conjugados de complejos metálicos macrocíclicos con biomoléculas y su uso para la preparación de medios de diagnóstico por resonancia magnética nuclear, radiodiagnóstico y radioterapia UY27389A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10135355A DE10135355C1 (de) 2001-07-20 2001-07-20 Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie

Publications (1)

Publication Number Publication Date
UY27389A1 true UY27389A1 (es) 2003-02-28

Family

ID=7692470

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27389A UY27389A1 (es) 2001-07-20 2002-07-17 Conjugados de complejos metálicos macrocíclicos con biomoléculas y su uso para la preparación de medios de diagnóstico por resonancia magnética nuclear, radiodiagnóstico y radioterapia

Country Status (19)

Country Link
US (2) US20030206865A1 (es)
EP (1) EP1450864A2 (es)
JP (1) JP2004536889A (es)
KR (1) KR20040030825A (es)
CN (1) CN1301750C (es)
AR (1) AR036182A1 (es)
AU (1) AU2002355333B2 (es)
BR (1) BR0211150A (es)
CA (1) CA2453214A1 (es)
DE (1) DE10135355C1 (es)
IL (1) IL159291A0 (es)
MX (1) MXPA04000400A (es)
NO (1) NO20040239L (es)
PE (1) PE20030190A1 (es)
PL (1) PL366421A1 (es)
RU (1) RU2004105262A (es)
TW (1) TWI238722B (es)
UY (1) UY27389A1 (es)
WO (1) WO2003013617A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632651B2 (en) 1997-09-15 2009-12-15 Mds Analytical Technologies (Us) Inc. Molecular modification assays
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
ES2518926T3 (es) * 2000-06-02 2014-11-05 Board Of Regents, The University Of Texas System Conjugados de etilendicisteína y un análogo de glucosa
DE10135356C1 (de) * 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
EP1466629A1 (en) * 2003-04-11 2004-10-13 BRACCO IMAGING S.p.A. Adducts between magnetic resonance shift reagents and substrates containing exchangeable protons for "CEST" applications
DE10325752A1 (de) * 2003-06-06 2004-12-30 Faustus Forschungs Cie. Translational Cancer Research Gmbh Lektin-Konjugate
FR2856689A1 (fr) * 2003-06-25 2004-12-31 Guerbet Sa Composes specifiques a forte relaxivite
WO2004112840A2 (en) * 2003-06-25 2004-12-29 Guerbet Peptide conjugate for magnetic resonance imaging
US20070258888A1 (en) * 2003-11-17 2007-11-08 Claus Feldmann Contrast Agent for Medical Imaging Techniques and Usage Thereof
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
FR2868320B1 (fr) * 2004-03-31 2007-11-02 Centre Nat Rech Scient Cnrse Agent de contraste pour l'imagerie par resonance magnetique
CA2581639C (en) 2004-09-30 2016-07-26 Molecular Devices Corporation Luminescent lanthanide complexes
US8734761B2 (en) 2005-04-26 2014-05-27 Koninklijke Philips N.V. Responsive MRI contrast agents
FI20055712A0 (fi) * 2005-12-29 2005-12-29 Wallac Oy Makrosykliset oligonukleotiidien leimausreagenssit ja niistä johdetut konjugaatit
US8758723B2 (en) * 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
CN102083427B (zh) 2008-01-09 2014-12-10 分子洞察制药公司 碳酸酐酶ix的抑制剂
US8211402B2 (en) 2008-12-05 2012-07-03 Molecular Insight Pharmaceuticals, Inc. CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer
WO2010065899A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
CN102272100B (zh) 2008-12-05 2016-08-17 分子制药洞察公司 用于抑制psma的锝-和铼-双(杂芳基)络合物及其使用方法
BR112012000210A2 (pt) 2009-06-15 2019-09-24 Molecular Insight Pharm Inc processo para a produção de heterodímeoros de ácido glutâmico.
CN101912623B (zh) * 2010-08-24 2012-06-06 上海师范大学 具有靶向功能铁-钆双模式磁共振造影剂的制备及应用
CN102136339B (zh) * 2011-01-24 2012-05-23 南开大学 一种具有铁磁、铁电双功能的镝单分子磁体及其制备方法
US9120837B2 (en) 2012-01-06 2015-09-01 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX
CN105025933B (zh) 2013-01-14 2019-03-26 分子制药洞察公司 三嗪类放射性药物和放射性显影剂
US20170050988A1 (en) * 2013-11-25 2017-02-23 Sanofi Dotam derivatives for therapeutic use
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
CA3044877A1 (en) 2016-11-28 2018-05-31 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
EA201992595A1 (ru) 2017-05-05 2020-04-21 Фьюжн Фармасьютикалс Инк. Усиление фармакокинетики бифункциональных хелатов и их применения
MA49398A (fr) 2017-05-05 2020-04-22 Eric Steven Burak Anticorps monoclonaux anti-igf-1r et utilisations de ceux-ci
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
KR20210095168A (ko) 2018-11-23 2021-07-30 바이엘 악티엔게젤샤프트 조영 매체의 제형 및 그의 제조 방법
FR3092580B1 (fr) * 2019-02-08 2021-03-19 Centre Nat Rech Scient Nouveaux dérivés azobenzènes, leur procédé de préparation et leur utilisation pour le traitement thérapeutique associé à des radiations ionisantes
EP3757098A1 (en) 2019-06-25 2020-12-30 Ustav Organicke Chemie a Biochemie AV CR, v.v.i. Cyclen based compounds, coordination compounds, peptides, pharmaceutical preparation, and use thereof
KR102203368B1 (ko) * 2020-10-30 2021-01-14 경북대학교 산학협력단 신규한 화합물 및 이를 함유하는 mri 조영제
US20250154159A1 (en) * 2022-03-16 2025-05-15 Wenzhou Institute University of Chinese Academy of Sciences CYCLIC Gd (III) COMPLEX AND PREPARATION METHOD AND USE THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049667A (en) * 1987-04-14 1991-09-17 Guerbet S.A. Nitrogen-containing cyclic ligands
JPH04154729A (ja) * 1990-10-16 1992-05-27 Nippon Mejifuijitsukusu Kk 磁気共鳴造影剤
DE4115789A1 (de) * 1991-05-10 1992-11-12 Schering Ag Makrocyclische polymer-komplexbildner, deren komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
CA2092596A1 (en) * 1992-03-27 1993-09-28 Kan Kubomura Tetraazacyclododecane derivative and its use
SG52459A1 (en) * 1992-12-09 1998-09-28 Boehringer Ingelheim Pharma Stabilized medicinal aerosol solution formulations
US6693190B1 (en) * 1994-05-11 2004-02-17 Bracco International B.V. Enhanced relaxivity monomeric and multimeric compounds
US6045776A (en) * 1996-12-04 2000-04-04 Schering Aktiengesellschaft Process for the production of metal-complex carboxylic acid amides
US6113880A (en) * 1997-12-17 2000-09-05 Schering Aktiengesellschaft Polyrotaxane derivatives for x-ray and nuclear magnetic resonance imaging
DE19905094C1 (de) * 1999-02-01 2000-10-12 Schering Ag Gadolinium (III)-Komplexe sowie ihre Verwendung für Zweischritt Strahlentherapieformen und diese enthaltende pharmazeutische Mittel

Also Published As

Publication number Publication date
EP1450864A2 (de) 2004-09-01
NO20040239L (no) 2004-01-19
AU2002355333B2 (en) 2007-01-04
CN1301750C (zh) 2007-02-28
CA2453214A1 (en) 2003-02-20
PL366421A1 (en) 2005-01-24
AR036182A1 (es) 2004-08-18
DE10135355C1 (de) 2003-04-17
WO2003013617A2 (de) 2003-02-20
KR20040030825A (ko) 2004-04-09
PE20030190A1 (es) 2003-03-22
IL159291A0 (en) 2004-06-01
RU2004105262A (ru) 2005-07-10
WO2003013617A3 (de) 2004-06-10
CN1541114A (zh) 2004-10-27
TWI238722B (en) 2005-09-01
JP2004536889A (ja) 2004-12-09
BR0211150A (pt) 2004-06-29
MXPA04000400A (es) 2004-03-18
US20030206865A1 (en) 2003-11-06
US20070014725A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
UY27389A1 (es) Conjugados de complejos metálicos macrocíclicos con biomoléculas y su uso para la preparación de medios de diagnóstico por resonancia magnética nuclear, radiodiagnóstico y radioterapia
UY27390A1 (es) Complejos metálicos macrocíclicos y su uso para la preparación de conjugados con biomoléculas
JP6462084B2 (ja) 線形加速器及び磁気共鳴撮像装置を互いに遮蔽する方法及び装置
AU2015311749B2 (en) Ferromagnetic augmentation for magnetic resonance imaging
Sessler et al. Texaphyrins: synthesis and applications
Dorazio et al. CoCEST: cobalt (II) amide-appended paraCEST MRI contrast agents
FI107157B (fi) Menetelmä terapeuttisesti käyttökelpoisten vesiliukoisten teksafyriinien metallikompleksien valmistamiseksi
AU2002355333A1 (en) Conjugates of macrocyclic metal complexes with biomolecules and the utilization thereof for producing agents for use in NMR diagnosis and radiodiagnosis and radiotherapy
DE69934827D1 (de) Amphipatische polycarboxylchelate und komplexe mit paramagnetischen metallen als mri kontrastmittel
Gunter et al. A model for the cyanide form of oxidized cytochrome oxidase: an iron (III)/copper (II) porphyrin complex displaying ferromagnetic coupling
WO1990010633A1 (en) Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
An et al. Multifunctional Magnetic Gd3+‐Based Coordination Polymer Nanoparticles: Combination of Magnetic Resonance and Multispectral Optoacoustic Detections for Tumor‐Targeted Imaging in vivo
Zhao et al. Enhanced cytotoxicity of benzimidazole carbamate derivatives and solubilisation by encapsulation in cucurbit [n] uril
JP2020535870A (ja) 同時撮像及びｂ０シミングのための磁気共鳴コイル
US20060280689A1 (en) New MRI technique based on electron spin resonance and nitrogen endohedral C60 contrast agent
Kruger et al. A portable CMOS-based MRI system with 67× 67× 83 µm 3 image resolution
SG151073A1 (en) Contrast agent for use in imaging methods
BR9508435A (pt) Quelentes macrocíclicos seus quelatos e usos dos mesmos no campo diagnóstico
Blake et al. Selective derivatisation of aza macrocycles
NO309481B1 (no) CNC-utvidete porfyriner, preparat og farmasöytisk preparat derav, magnetisk-resonans-avbildnings-(MRI)-kontrastmiddel, samt fremgangsmåte for fremstilling
DE59906695D1 (de) Paramagnetische 3-,8-substituierte deuteroporphyrinderivate, diese enthaltende pharmazeutische mittel, verfahren zu ihrer herstellung und ihre verwendung für das nekrose- und infarkt-mr-imaging
UY29664A1 (es) Complejos metalicos con contenido de prfluoroalquilo procedimientos para su preparacion, a´si como su uso
US20040097723A1 (en) Carbene porphyrins and carbene porphyrinoids, methods of preparation and uses thereof
Korszun et al. Extended X-ray absorption fine structure study of Rhodospirillum rubrum and Rhodospirillum molischianum cytochromes c': relationship between heme stereochemistry and spin state
Faustino Evaluation of metalloporphyrins as contrast agents for tumors in magnetic resonance imaging

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126